15 December 2016Americas

UCB sues MedImmune for patent infringement

Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.

The case, which was filed in the US District Court for the District of Delaware on Monday, December 12, centred on MedImmune’s Synagis (palivizumab), a therapy used to help prevent lung disease.

UCB owns the patent involved, US number 7,566,771, titled “Humanised antibodies”. It was issued by the US Patent and Trademark Office in July 2009.

The ‘771 patent was granted to Celltech R&D, but UCB is now the owner.

According to the suit, MedImmune’s sale of Synagis has infringed the ‘771 patent since at least January 2011.

In 1998 a Celltech predecessor company licensed a patent (which became the ‘771 patent) to a predecessor of MedImmune, but in 2011 MedImmune terminated the licence.

UCB has asked for triple damags.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 May 2018   Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.

More on this story

Americas
24 May 2018   Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.

More on this story

Americas
24 May 2018   Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.